Clinical data to date shows efti uniquely positioned to address entire NSCLC patient population through both chemo-free IO-IO and IO-IO-chemo triple combinations
The data from this study show that MM-II has the potential to provide durable pain relief for our patients
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
This new capability represents a significant shift from a microscope-based standard of care to the use of digital whole slide images
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Diagnostic imaging will become an increasingly vital process in healthcare
The company has operationalized diagnostics center at Ferozepur, Gurdaspur, Nawanshahr, and Kapurthala in Punjab.
The lab is also the first private lab in West India to have built its Mycobacteriology, Mycology, and Molecular Biology departments within a separate Bio Safety Level - 3 (BSL3) bio-containment lab
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Subscribe To Our Newsletter & Stay Updated
